Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Overview 6
Therapeutics Development 7
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Stage of Development 7
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Therapy Area 8
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Indication 9
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Companies 12
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Companies Involved in Therapeutics Development 18
ArQule, Inc. 18
Astex Pharmaceuticals Inc 19
Eddingpharm 20
Merck KGaA 21
PharmAust Limited 22
Phoenix Biotechnology, Inc. 23
Sentinel Oncology Limited 24
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drug Profiles 25
AT-13148 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
EDP-317 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
M-2698 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
monepantel - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
PBI-05204 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecule To Inhibit S6K1 For Breast Cancer - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Inhibit S6K for Oncology - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Dormant Projects 34
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Discontinued Products 35
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Featured News & Press Releases 36
Jul 11, 2016: Juniper Pharma Successfully Completes Manufacture of Reformulated MPL Capsules 36
Jan 29, 2016: PharmAust Limited Announced Quarterly Report & Company Update For the period ended 31 December 2015 36
Nov 26, 2015: PharmAust Appoints GenScript to Complete Further Pre-Clinical Validation for Phase II Trial 37
Jan 17, 2013: Cancer Research UK And Cancer Research Technology Launches Phase I Clinical Trial With AT13148 To Treat Several Cancer Types 38
Jan 16, 2013: Astex Pharma Announces Cancer Research UK And Cancer Research Technology Initiate AT13148 Clinical Trial To Treat Several Cancer Types 39
Jul 10, 2012: Experimental Drug Could Treat Different Cancers, New Research Says 40
Jan 22, 2010: ACT BIOTECH Announces FDA Acceptance Of IND For ACTB1003, A First-in-Class Anti-Cancer Therapeutic 40
Oct 18, 2007: Astex Drug Candidates To Be Featured At The 2007 AACR-NCI-EORTC International Conference 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 15
Number of Products by Stage and Route of Administration, H2 2016 16
Number of Products by Stage and Molecule Type, H2 2016 17
Pipeline by ArQule, Inc., H2 2016 18
Pipeline by Astex Pharmaceuticals Inc, H2 2016 19
Pipeline by Eddingpharm, H2 2016 20
Pipeline by Merck KGaA, H2 2016 21
Pipeline by PharmAust Limited, H2 2016 22
Pipeline by Phoenix Biotechnology, Inc., H2 2016 23
Pipeline by Sentinel Oncology Limited, H2 2016 24
Dormant Projects, H2 2016 34
Discontinued Products, H2 2016 35

List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Actions, H2 2016 15
Number of Products by Stage and Routes of Administration, H2 2016 16
Number of Products by Stage and Molecule Type, H2 2016 17